Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02143388

Recruitment Status : Completed

First Posted : May 21, 2014

Last Update Posted : August 31, 2022

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Jiangxi Provincial Cancer Hospital

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

National Cancer Centre, Singapore

Information provided by (Responsible Party):

Zhao Chong, Sun Yat-sen University

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	July 27, 2018
Actual Study Completion Date :	August 5, 2022

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Miao J, Wang L, Tan SH, Li JG, Yi J, Ong EHW, Tan LLY, Zhang Y, Gong X, Chen Q, Xiang YQ, Chen MY, Guo Y, Lv X, Xia WX, Tang L, Deng X, Guo X, Han F, Mai HQ, Chua MLK, Zhao C. Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA Oncol. 2022 Oct 13;8(12):1776-85. doi: 10.1001/jamaoncol.2022.4656. Online ahead of print.

To Top